Ir para o conteúdo principal

Collegium Pharmaceutical (NASDAQ: COLL) — Perfil da empresa, notícias e dados financeiros

Logo de Collegium Pharmaceutical
COLL Collegium Pharmaceutical
Collegium Pharmaceutical primary media
Perfil da empresa

Collegium Pharmaceutical

Collegium Pharmaceutical (NASDAQ:COLL) is a specialized company focusing on the development and commercialization of innovative therapies for pain management. The company aims to address the significant challenges in the pain management sector, such as the need for safer, abuse-deterrent formulations. Collegium Pharmaceutical is passionate about improving the lives of people suffering from pain and chronic conditions, guiding its project selection and research strategies towards achieving this goal. With a strong commitment to patient care, the company continuously seeks to advance its product portfolio through rigorous research and development, while also exploring strategic partnerships and acquisitions to expand its market reach. The objectives of Collegium Pharmaceutical revolve around delivering high-quality, effective treatments, and ensuring accessibility to those in need, thereby making a meaningful difference in the healthcare landscape.

Resumo

Public USParticipação acionária
2002Ano de fundação
231Funcionários
Massachusetts, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Collegium Pharmaceutical

  • Xtampza ER (oxycodone hydrochloride and naloxone hydrochloride) Extended-Release Tablets: A prescription pain medication used to manage moderate to severe chronic pain when other pain medications are not strong enough.
  • Nucynta (hydrocodone bitartrate and acetaminophen) Tablets: A prescription pain medication used to manage moderate to severe pain when other pain medications are not strong enough.
  • Development Pipeline: Collegium also has a development pipeline of potential future products focused on pain management and addiction treatment.

equipe executiva do Collegium Pharmaceutical

  • Vikram KarnaniCEO, President & Director
  • Colleen TupperExecutive VP & CFO
  • David DieterExecutive VP, General Counsel & Corporate Secretary
  • Thomas B. SmithExecutive VP & Chief Medical Officer
  • Ian KarpHead of Investor Relations
  • Jessica CotroneSenior Vice President of Corporate Communications & Corporate Affairs
  • Jane GonnermanExecutive Vice President of Strategy & Corporate Development
  • Dean J. PatrasChief People Officer
  • Scott SudduthEVP & Head of Technical Operations

Principais indicadores financeiros

Resultados divulgados pela Collegium Pharmaceutical, em USD.

Cap. de mercado
756,3 mi
Receita (TTM)
808,2 mi
P/L
18.3
LPA (diluído, TTM)
1.3
Dividend yield
—
Margem de lucro
5.9%
Receita e lucro anuais da Collegium Pharmaceutical
Fim do ano fiscalReceitaResultado operacionalLucro líquido
780,6 mi187,1 mi62,9 mi
631,4 mi169,9 mi69,2 mi
566,8 mi167 mi48,2 mi
463,9 mi33,3 mi-25 mi